Retatrutide 20mg

Retatrutide 20mg

Retatrutide

Retatrutide is a next-generation triple-agonist peptide that targets the GLP-1, GIP, and glucagon receptors. It is currently being studied for its role in metabolic regulation, appetite signalling, and energy expenditure pathways associated with body weight management and metabolic health research.

Unlike dual-agonist peptides, Retatrutide’s activity across three metabolic receptors is being investigated for its potential to influence satiety signalling, glucose metabolism, and lipid utilisation in laboratory settings.

Supplied as a lyophilised (freeze-dried) peptide powder in sterile research vials.

Contents: 20mg Retatrutide per vial.

Research category: Metabolic & weight regulation.

For laboratory research use only.
Not intended for human consumption, medical use, or diagnostic purposes.